advertisement
Science News
from research organizations

Immune T cell defense is coping with COVID-19 variants of concern -- for now

Broad T-cell response is currently protective but recognition of seven out of ten T-cell targets mutated in SARS-CoV-2 variants is impaired

Date:
December 1, 2022
Source:
University of Birmingham
Summary:
Immune T cells are continuing to target the spike protein of SARS-CoV-2 variants of concern, although mutations are making some T cells less effective, according to new research.
Share:
advertisement

FULL STORY

Immune T cells are continuing to target the spike protein of SARS-CoV-2 variants of concern, although mutations are making some T cells less effective, according to new research.

Published inNature Immunology, researchers from the University of Birmingham have shown that human T cell immunity is currently coping with mutations that have accumulated over time in COVID-19 variants.

In the study, funded by the National Institute for Health and Care Research, the research partner of the NHS, the researchers tested CD4+ T cells collected at the start of the pandemic from healthcare workers infected with COVID-19.

Some of the T-cells were still able to recognise parts of the spike protein, called epitopes, unaltered in later virus strains including the current Omicron variant. However, T cell recognition was worse against seven out of ten epitopes mutated in different variants of concern.

The researchers caution that as SARS-CoV-2 continues to mutate, T-cell recognition of additional epitopes could be lost decreasing overall protection by the immune system.

Dr Heather Long, Associate Professor in the Institute of Immunology and Immunotherapy at the University of Birmingham and lead author of the research said:

"Our paper shows that although most people have a diverse T cell response against the virus, some responses are less effective against Omicron. As further variants of concern are identified we will need to consider carefully how new viral mutations affect T-cell recognition."

Insti格雷厄姆·泰勒博士,副教授tute of Immunology and Immunotherapy at the University of Birmingham said:

"The vaccines currently in use are still vital to protect us from COVID-19. Should SARS-CoV-2 continue to mutate to evade the immune system, our findings will help researchers to develop new vaccines better suited to those variants."

advertisement

Story Source:

Materialsprovided byUniversity of Birmingham.注意:内容可能被编辑风格d length.


Journal Reference:

  1. Emily X. C. Tye, Elizabeth Jinks, Tracey A. Haigh, Baksho Kaul, Prashant Patel, Helen M. Parry, Maddy L. Newby, Max Crispin, Nayandeep Kaur, Paul Moss, Samantha J. Drennan, Graham S. Taylor, Heather M. Long.Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition.Nature Immunology, 2022; DOI:10.1038/s41590-022-01351-7

Cite This Page:

University of Birmingham. "Immune T cell defense is coping with COVID-19 variants of concern -- for now: Broad T-cell response is currently protective but recognition of seven out of ten T-cell targets mutated in SARS-CoV-2 variants is impaired." ScienceDaily. ScienceDaily, 1 December 2022. /releases/2022/12/221201123141.htm>.
University of Birmingham. (2022, December 1). Immune T cell defense is coping with COVID-19 variants of concern -- for now: Broad T-cell response is currently protective but recognition of seven out of ten T-cell targets mutated in SARS-CoV-2 variants is impaired.ScienceDaily. Retrieved August 20, 2023 from www.koonmotors.com/releases/2022/12/221201123141.htm
University of Birmingham. "Immune T cell defense is coping with COVID-19 variants of concern -- for now: Broad T-cell response is currently protective but recognition of seven out of ten T-cell targets mutated in SARS-CoV-2 variants is impaired." ScienceDaily. www.koonmotors.com/releases/2022/12/221201123141.htm (accessed August 20, 2023).

Explore More
from ScienceDaily

RELATED STORIES